Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Q1 2025 Earnings Call Transcript May 12, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 st ...

Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS).

Q1 2025 Earnings Call Transcript May 7, 2025 ACADIA Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $0.11, ...

The 17-year-old girl was diagnosed with a neuro attack, which landed her on a wheelchair, but her grit and confidence to ...

This initiative aligns with Sandoz’s ongoing efforts to support Egypt’s Vision 2030 and local healthcare authorities’ ...

Soleno Therapeutics Inc (SLNO) reports a strong initial market response to Vykat XR despite a significant net loss and high operational expenses in Q1 2025.

The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening ...

Learn more about whether ACADIA Pharmaceuticals Inc. or BioCryst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.